- Home
- PHAR vs PRCH Comparison
PHAR vs PRCH Comparison
Compare PHAR & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | PRCH |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 753.7M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHAR | PRCH |
|---|---|---|
| Price | $18.36 | $7.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $38.33 | $18.00 |
| AVG Volume (30 Days) | 12.9K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 90.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $482,414,000.00 |
| Revenue This Year | $10.04 | $3.89 |
| Revenue Next Year | $2.51 | $16.80 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | ★ 10.18 |
| 52 Week Low | $8.05 | $4.65 |
| 52 Week High | $21.34 | $19.44 |
Technical Indicators
Market Signals| Indicator | PHAR | PRCH |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 55.30 |
| Support Level | $16.90 | $6.54 |
| Resistance Level | $17.70 | $8.00 |
| Average True Range (ATR) | 0.64 | 0.44 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 61.10 | 81.53 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.